Heartseed (219A) · RiskWorsened
Dependence on specific pipelines
First written in FY2024. 1 of 2 entries say "Worsened", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Dependence on a Specific Pharmaceutical PipelineA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025WorsenedAnnual report
「As a result, dependence on revenue from the lead pipeline HS-001 will increase, and the Company's results and business development may become heavily dependent on the development and sales status of that product.」
Because HS-005 is in the early stages of the EMERALD trial and new pipelines are in the basic research stage, the Company explicitly states that revenue dependence on HS-001 may increase following termination of the partnership. - FY2024First statedAnnual report
「Even if commercialization is possible, it is expected to require a considerable amount of time and expense. In addition, constraints include technical difficulties, competitors' development lead and technological innovation, regulations, shortages of personnel and uncertainty in establishing a supply chain.」
Although the Company is advancing multiple pipelines, it identifies the risk of a potentially increasing dependence on HS-001.